Search terms
Results 1 - 5 of 5 - ordered by :

Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with stable coronary or peripheral artery disease, according to late-breaking results from the COMPASS trial ...

Date : 27/08/2017

Patients with stable atherosclerotic vascular disease who take rivaroxaban (2.5mg twice daily) plus aspirin (100mg once daily) have better cardiovascular outcomes than those who take aspirin alone, ...

Date : 28/08/2017

In a Clinical Trial Updates session yesterday, Doctor John Eikelboom (McMaster University, Hamilton, Ontario, Canada) discussed new data relating to the types and timing of bleeding, and association ...

Date : 27/08/2018

The European Society of Cardiology (ESC) Working Group on Thrombosis is calling for greater attention to be paid by health care staff to reducing bleeding in patients with acute coronary syndromes ...

Date : 30/06/2011

Professor John Eikelboom, principal investigator, of the Population Health Research Institute, McMaster University, Hamilton, Canada, said: “In patients with stable coronary artery disease or ...

Date : 26/08/2018